
Guiding DAPT De-escalation With Platelet Function Testing Doesn’t Improve Outcomes: EPIC17-VERONICA bit.ly/4kRsHiB

Interventional cardiologist, science & technology geek. Linked to @foroepic (open discussion forum on interventional cardiology) @fundacionepic @fundepicmedia

Guiding DAPT De-escalation With Platelet Function Testing Doesn’t Improve Outcomes: EPIC17-VERONICA bit.ly/4kRsHiB

Cerramos el #CSC2026 en Madrid ❤️ Hemos donado 2.000 € a @MenudosMenudos de la mano de @CARDIVAGROUP, dentro de la campaña #FlechazoSolidario. ¡Nos hace muchísima ilusión! Gracias a los dos y a todos los partners que nos habéis acompañado estos días 💙

Diez años de historias, de personas y de compromiso. ✨ El 28 de enero celebramos la Gala X Aniversario de Fundación EPIC en el Palacete de los Duques de Pastrana. Nos vemos allí. 🤍 #FundaciónEPIC #XAniversario

¿Demasiadas pastillas en coronarios? #POLICROSS, estudio liderado por el Dr. I. Lozano de Cardiología de @CAHU3Oriente: la polipíldora mejora la adherencia y el control de tensión y colesterol. Muy interesante estudio.@foroic doi.org/10.1016/j.jacc.2026.…

🫀 EPIC17-VERONICA, ensayo español del #TCT2026: en 637 pacientes tras un SCA con baja reactividad plaquetaria, pasar a clopidogrel no redujo los eventos clínicos netos frente a seguir con prasugrel o ticagrelor (11,9% vs 13,2%). solaci.org/2026/11/05/tct-20… #Hemodinamica

TAVRfy: tavrfy.com sizing de TAVR en español y gratis. Con el perímetro o el área del anillo, muestra dónde cae en los rangos de cada fabricante. @evandrofilhobr @lamelaspablo @pbaglioni @solaci_online @sbhci @SAC_54 @santiagosergas #TAVI #hemodinamia

Dr. Iñigo Lozano and Dr. C. Michael Gibson discuss the EPIC17-VERONICA trial: De-escalation from potent P2Y12 inhibitors to clopidogrel guided by platelet reactivity testing did not significantly reduce net adverse clinical events at 12 months in ACS patients with low platelet reactivity. Watch video here: clinicaltrialresults.org/wp-…

EPIC17-VERONICA trial: Platelet reactivity testing to guide P2Y12 inhibitor de-escalation showed a neutral effect on the primary endpoint of net adverse clinical events at 12-month follow-up in ACS patients with very low platelet reactivity, demonstrating no significant reduction in events compared with continuation of potent P2Y12 inhibitors. Download slides here: clinicaltrialresults.org/wp-…

DUOTAP trial: Routine post-dilatation with the original delivery balloon at the identical filling volume achieved a 70% reduction in the transcatheter heart valve asymmetry index at 30 days in patients with severe aortic stenosis undergoing transfemoral transcatheter aortic valve implantation with a balloon-expandable valve, demonstrating optimized transcatheter heart valve geometry and improved expansion. Download slides here: clinicaltrialresults.org/wp-…

More to share: clinicaltrialresults.org/dr-…




EPIC day! @inigolozanomar shows the results of #Epic17-Veronica RCT #LBCT_MainArena #TCT26 Kudos to all the investigators @fundacionepic Stay tuned!

Dr. Carlos Collet and Dr. C. Michael Gibson discuss the P4 Trial: Comprehensive CCTA-guided PCI strategy was associated with a lower rate of target vessel failure at 12 months compared to IVUS-guided PCI (4.1% vs. 4.8%) among patients with chronic coronary syndrome or stabilized acute coronary syndrome, supporting procedural safety and non-inferiority. Watch video here: clinicaltrialresults.org/wp-…

#TCT26 #LBCT @BernardCortese Shows the impressive results of #TRANSFORM2 Accepted for publication in @TheLancet